Inovio Pharmaceuticals Announces 1-4 Reverse Split for INO Stock

by Christopher Freeburn | May 23, 2014 11:15 am

On Friday, Inovio Pharmaceuticals (INO[1]) announced that its shareholders had approved 1-for-4 reverse stock split[2] of Inovio common stock. INO shares sank more than 5% in morning trading.

inovio 185[3]Inovio said that the effective date of the reverse stock split would be disclosed at a future date after Inovio complies with “standard NYSE administrative processes.”

In a statement, Inovio President and CEO Dr. J. Joseph Kim said: “Our stockholders approved a reverse split to have our price and share structure reflect our leadership position in immunotherapies and expand our potential investor audience.”

Inovio is developing vaccines against HPV-caused pre-cancers and cancers, prostate, breast, and lung cancers, and HIV, influenza, malaria and hepatitis.

More Pharma Stock News:

  1. INO:
  2. had approved 1-for-4 reverse stock split:
  3. [Image]:
  4. MRK: Merck Sells Consumer Business to Double Down on Blockbusters:
  5. Is AstraZeneca a Buy After Pfizer Breakup? 3 Pros, 3 Cons:
  6. Hottest Healthcare Stocks Now – CAH PDLI SHPG FRX:

Source URL:
Short URL: